treatment, patient education, and nursing measures. Using the format here, you are invited to submit your "Clinical Snapshot" to Dermatology Nursing. Epidermolysis bullosa (EB) is the term given ...

Long-term treatment with Oleogel-S10 was well tolerated in patients with epidermolysis bullosa, in the 24-month open-label ...

The FDA has approved Krystal Biotech’s gene therapy Vyjuvek for dystrophic epidermolysis bullosa (DEB), a rare ... Before now, the only treatment was palliative care. Vyjuvek – which has ...

approved a new gene therapy gel for the treatment of a specific type of butterfly disease in patients who are at least 6 months old. Called dystrophic epidermolysis bullosa, this form of the ...

Abeona Therapeutics Inc.'s promising gene therapy for RDEB, potential FDA approval, undervalued stock, and key risks. Click ...

its drug for rare and debilitating skin disease epidermolysis bullosa (EB). Shares in the Ireland-based rare disease specialist fell sharply after news of the complete response letter (CRL ...

INmune Bio’s (INMB) treatment of epidermolysis bullosa received FDA orphan designation, according to a post on the agency’s site. Published first on TheFly – the ultimate source for real ...

It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials ...

as a potential new treatment for recessive dystrophic epidermolysis bullosa (RDEB). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025. "The FDA ...

In May 2023, the FDA approved Vyjuvek, the first-ever revocable gene therapy for treating patients aged six months or older with dystrophic epidermolysis bullosa ... VEC for the treatment of ...